Compounds and pharmaceutical use thereof in the treatment of cancer

A method of treating a disease treatable by inhibiting CD47 function in a subject in need thereof comprising administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof comprising a hexapeptide sequence of formula (I):

• —X1—X2—X3—X4—X5—X6— (I)
• wherein:
• X1, X2, X3, X4, X5, X6 are independently linked to each other according to formula (I) via peptide bonds or at least one pseudopeptide bond;
• X1 is a residue chosen from the list consisting of substituted or unsubstituted phenylalanine, substituted or unsubstituted para-tyrosine, substituted or unsubstituted ortho-tyrosine, substituted or unsubstituted meta-tyrosine, and substituted or unsubstituted homo-phenylalanine;
• X2 is a residue chosen from the list consisting of substituted or unsubstituted para-tyrosine, substituted or unsubstituted ortho-tyrosine, substituted or unsubstituted meta-tyrosine, substituted or unsubstituted phenylalanine, homo-phenylalanine, homo-meta-tyrosine, homo-para-tyrosine and homo-ortho-tyrosine;
• X3 is a residue chosen from the list consisting of substituted or unsubstituted valine, substituted or unsubstituted alanine, substituted or unsubstituted leucine, and substituted or unsubstituted isoleucine;
• X4 is a residue chosen from the list consisting of substituted or unsubstituted valine, substituted or unsubstituted alanine, substituted or unsubstituted leucine, substituted and unsubstituted isoleucine;
• X5 is a residue chosen from the list consisting of substituted or unsubstituted methionine, methylated homo-cysteine, lysine, norleucine, leucine and isoleucine;
• X6 is a residue chosen from the list consisting of substituted or unsubstituted tryptophan, substituted or unsubstituted hetero-tryptophan, substituted or unsubstituted para-tyrosine, substituted or unsubstituted ortho-tyrosine, substituted or unsubstituted meta-tyrosine, substituted or unsubstituted phenylalanine, and substituted or unsubstituted naphthyl-alanine;
• X1 is the N-terminal side of the molecule of formula (I), X6 is the C-terminal side of the molecule of formula (I);
• the hexapeptide sequence of formula (I) comprises at least one substituted or unsubstituted para-tyrosine, substituted or unsubstituted ortho-tyrosine, substituted or unsubstituted meta-tyrosine residue,
• wherein said compound is an agonist of CD47,
• with the proviso that none of the following peptides are covered:
• KRFYGGMWKK
• (D)KRFYGGMW(D)K
• KRFYVVMWKK
• ( )R-F-Y-V-V-M-W-K
• R-( )F-Y-V-V-M-W-K
• R-F-( )Y-V-V-M-W-K
• R-F-Y-( )V-V-M-W-K
• R-F-Y-V-( )V-M-W-K
• R-F-Y-V-V-( )M-W-K
• R-F-Y-V-V-M-( )W-K
• R-F-Y-V-V-M-W-( )K
• ( )R-( )F-( )Y-( )V-( )V-( )M-( )W-
• ( )K
• ( )K-( )W-( )M-( )V-( )V-( )Y-( )F-
• ( )R
• Azido( )K-( )W-( )M-( )V-( )V-( )Y-
• ( )F-( )R
• ( )K-R-F-Y-V-V-M-W-K-K
• K-( )R-F-Y-V-V-M-W-K-K
• K-R-( )F-Y-V-V-M-W-K-K
• K-R-F-( )Y-V-V-M-W-K-K
• K-R-F-Y-( )V-V-M-W-K-K
• K-R-F-Y-V-( )V-M-W-K-K
• K-R-F-Y-V-V-( )M-W-K-K
• K-R-F-Y-V-V-M-( )W-K-K
• R-R-F-V-V-V-M-W-( )K-K
• R-R-F-V-V-V-M-W-K-( )K
• K-R-F-Y-V-V-M-W-K-( )R
• ( )K-R-F-Y-V-V-M-W-K-( )K
• ( )K-( )R-( )F-( )Y-( )V-( )V-( )M-
• ( )W-( )K-( )K
• ( )K-( )K-( )W-( )M-( )V-( )V-( )Y-
• ( )F-( )R-( )K
• wherein R7 refers to methionine, methionine sulfoxide, methionine sulfone or alanine or butylglycine or lysine side chains,
• wherein R4 refers to methionine or alanine or butylglycine or lysine side chains;